Skip to content

Arno Therapeutics, Inc: 10-K filed 2014-03-31

What Arno Therapeutics, Inc reported in its annual report filed 2014-03-31 (fiscal FY 2013): 31 published measures, 91 facts as tagged in accession 0001144204-14-019511.

This filing

Form
10-K (annual report)
Filed
2014-03-31
Fiscal period
fiscal FY 2013
Accession
0001144204-14-019511 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Arno Therapeutics, Inc filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-12-3126,882,644USD
At 2012-12-3112,891,775USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-12-3139,765,970USD
At 2012-12-3125,157,607USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-12-31-12,883,326USD
At 2012-12-31-12,265,832USD
At 2011-12-311,355,639USD
At 2010-12-318,435,820USD
At 2009-12-311,575,751USD
At 2008-12-317,862,408USD
At 2007-12-31-3,627,590USD
At 2006-12-31-356,193USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-12-3126,774,203USD
At 2012-12-3110,943,437USD
At 2011-12-316,678,344USD
At 2005-07-310USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-12-31-39,656,975USD365
2005-08-01 to 2013-12-31-89,557,757USD3075
2012-01-01 to 2012-12-31-14,387,782USD366
2011-01-01 to 2011-12-31-7,909,113USD365
2010-01-01 to 2010-12-31-4,023,026USD365
2009-01-01 to 2009-12-31-6,936,705USD365
2008-01-01 to 2008-12-31-12,913,566USD366
2007-01-01 to 2007-12-31-3,359,697USD365
2006-01-01 to 2006-12-31-370,893USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-12-31-14,242,576USD365
2005-08-01 to 2013-12-31-52,399,042USD3075
2012-01-01 to 2012-12-31-9,419,762USD366

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-01-01 to 2013-12-310USD365
2005-08-01 to 2013-12-31100,174USD3075
2012-01-01 to 2012-12-310USD366

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-12-3130,073,342USD365
2005-08-01 to 2013-12-3179,358,544USD3075
2012-01-01 to 2012-12-3113,684,855USD366

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-01-01 to 2013-12-310USD365
2005-08-01 to 2013-12-31-185,299USD3075
2012-01-01 to 2012-12-310USD366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2008-06-03120,538USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-12-3111,720USD
At 2012-12-3124,837USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-01-01 to 2013-12-311,456,776USD365
2005-08-01 to 2013-12-315,127,991USD3075
2012-01-01 to 2012-12-31722,811USD366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-12-31-16,940,549USD365
2005-08-01 to 2013-12-31-63,128,369USD3075
2012-01-01 to 2012-12-31-10,835,801USD366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-12-3126,860,469USD
At 2012-12-3111,146,953USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-01-01 to 2013-12-3118,569,157USD365
2005-08-01 to 2013-12-3126,190,285USD3075
2012-01-01 to 2012-12-316,361,029USD366

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-12-313,901,089USD
At 2012-12-313,246,292USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-12-312,941,998USD
At 2012-12-311,553,154USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2013-01-01 to 2013-12-3116,940,549USD365
2005-08-01 to 2013-12-3163,128,369USD3075
2012-01-01 to 2012-12-3110,835,801USD366

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-01-01 to 2013-12-3113,476,369USD365
2005-08-01 to 2013-12-3150,321,577USD3075
2012-01-01 to 2012-12-318,537,130USD366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-12-3120,370,331shares
At 2012-12-314,545,618shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-12-3176,668,966USD
At 2012-12-3137,631,339USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2013-12-3178,412USD
At 2012-12-3178,412USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2013-12-31-66,692USD
At 2012-12-31-53,575USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2013-12-3186,266USD
At 2012-12-31203,516USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2013-12-310USD
At 2012-12-310USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-12-313,464,180USD365
2005-08-01 to 2013-12-3112,806,792USD3075
2012-01-01 to 2012-12-312,298,671USD366

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2013-01-01 to 2013-12-3113,117USD365
2005-08-01 to 2013-12-3183,096USD3075
2012-01-01 to 2012-12-3113,836USD366

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2013-01-01 to 2013-12-31-4,165,006USD365
2005-08-01 to 2013-12-31-670,960USD3075
2012-01-01 to 2012-12-312,801,199USD366

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2013-01-01 to 2013-12-31-22,716,426USD365
2005-08-01 to 2013-12-31-26,429,388USD3075
2012-01-01 to 2012-12-31-3,551,981USD366

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2013-01-01 to 2013-12-3119,425,340USD365
2005-08-01 to 2013-12-3137,115,377USD3075
2012-01-01 to 2012-12-310USD366

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-12-311,388,844USD365
2005-08-01 to 2013-12-312,941,998USD3075
2012-01-01 to 2012-12-31869,993USD366

Inspect the source

Entity
Arno Therapeutics, Inc / CIK 0001195116
Captured
SEC response SHA-256
daf59b1b66be981617a28a70398e42d86562bef04d5c645d4ccff16477481049

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001195116.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))